Want to see ARTV full AI Analyst Report?
Top Page
Artiva Biotherapeutics, Inc.
(NASDAQ:ARTV)
Select Model
Select Model
Rating:40Underperform
Price Target:
$6.00
▼(-49.02% Downside)
Action:Downgraded
Date:10/27/26
The score is driven primarily by weak financial performance (zero revenue, large losses, and substantial cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Negative corporate developments—ending the lead program and large workforce reduction—add significant risk, while valuation is difficult to justify on a negative P/E and no dividend support.
Positive Factors
Low Leverage
Very low leverage reduces refinancing pressure and preserves financial flexibility during the company’s strategic review. A modest debt burden limits mandatory cash commitments, although it does not offset the need to control operating losses or fund future development.
Negative Factors
No Commercial Revenue
The absence of current revenue leaves Artiva without a commercial operating base to support its substantial costs. Persistent losses and the sharp revenue deterioration indicate that earnings power remains dependent on successful development, financing, or a strategic transaction rather than established product sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage reduces refinancing pressure and preserves financial flexibility during the company’s strategic review. A modest debt burden limits mandatory cash commitments, although it does not offset the need to control operating losses or fund future development.
Read all positive factors
Artiva Biotherapeutics, Inc. (ARTV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$301.16M
Dividend YieldN/A
Average Volume (3M)516.02K
Price to Earnings (P/E)―
Beta (1Y)2.77
Revenue GrowthN/A
EPS Growth-7.24%
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.31
Shares Outstanding48,890,120
10 Day Avg. Volume459,420
30 Day Avg. Volume516,024
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.21
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$35.00Price Target Upside197.37% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-2.59
Revenue Forecast (FY)N/A
Artiva Biotherapeutics, Inc. Business Overview & Revenue Model
Company Description
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeu...
How the Company Makes Money
null...
Artiva Biotherapeutics, Inc. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 251.00K | 33.49M | 4.93M | 2.00M |
| Gross Profit | -666.00K | -2.60M | 251.00K | 33.49M | 4.93M | 2.00M |
| EBITDA | -87.47M | -81.27M | -56.06M | -25.36M | -57.18M | -71.58M |
| Net Income | -90.82M | -83.86M | -58.49M | -27.70M | -58.39M | -71.83M |
Balance Sheet | ||||||
| Total Assets | 368.63M | 130.94M | 209.58M | 105.11M | 133.05M | 169.93M |
| Cash, Cash Equivalents and Short-Term Investments | 349.39M | 108.01M | 185.43M | 76.97M | 102.53M | 160.92M |
| Total Debt | 9.85M | 10.94M | 14.35M | 16.91M | 19.45M | 1.74M |
| Total Liabilities | 21.13M | 20.97M | 22.94M | 267.13M | 273.75M | 258.78M |
| Stockholders Equity | 347.50M | 109.97M | 186.64M | -162.01M | -140.70M | -88.86M |
Cash Flow | ||||||
| Free Cash Flow | -98.10M | -79.34M | -55.67M | -50.69M | -57.13M | -17.03M |
| Operating Cash Flow | -96.18M | -76.75M | -55.03M | -47.43M | -50.83M | -15.30M |
| Investing Cash Flow | 80.53M | 63.41M | -120.46M | -25.98M | -6.30M | -1.72M |
| Financing Cash Flow | 282.89M | 9.00K | 162.23M | 24.39M | -1.26M | 152.75M |
Artiva Biotherapeutics, Inc. Technical Analysis
Negative
11.77
Price Trends
8.70
Negative
9.19
Negative
8.04
Negative
Market Momentum
-0.66
Negative
34.39
Neutral
39.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Negative. The current price of 11.77 is above the 20-day moving average (MA) of 6.56, above the 50-day MA of 8.70, and above the 200-day MA of 8.04, indicating a bearish trend. The MACD of -0.66 indicates Negative momentum. The RSI at 34.39 is Neutral, neither overbought nor oversold. The STOCH value of 39.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTV.
Artiva Biotherapeutics, Inc. Risk Analysis
Artiva Biotherapeutics, Inc. disclosed 91 risk factors in its most recent earnings report. Artiva Biotherapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artiva Biotherapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $36.88M | -0.34 | -74.90% | <0.01% | ― | 44.73% | |
48 Neutral | $16.82M | -0.32 | -618.87% | ― | ― | 73.74% | |
44 Neutral | $52.62M | -0.57 | -53.22% | ― | ― | 55.84% | |
42 Neutral | $28.03M | -3.56 | -71.47% | ― | -100.00% | -55.90% | |
40 Underperform | $301.16M | -1.86 | -53.86% | ― | ― | -7.24% |
* Healthcare Sector Average
ARTV
Artiva Biotherapeutics, Inc.
6.16
1.43
30.23%
ACET
Adicet Bio
3.94
-9.75
-71.22%
ABVC
ABVC BioPharma
1.05
-1.86
-63.92%
JSPR
Jasper Therapeutics
0.51
-1.84
-78.42%
PLRX
Pliant Therapeutics
0.85
-0.93
-52.30%
Artiva Biotherapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Artiva Biotherapeutics Ends AlloNK Program, Explores Strategic Options
Negative
Oct 27, 2026
On October 27, 2026, Artiva Biotherapeutics announced it would discontinue further clinical development of its lead AlloNK (AB-101) NK cell therapy program after reviewing updated longer-term clinical data and serious safety events, including two ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Artiva Biotherapeutics Expands Equity Plan, Elects Directors
Positive
Sep 11, 2026
On September 8, 2026, Artiva Biotherapeutics held its 2026 annual meeting of stockholders, where shareholders approved an amendment to the company’s 2024 Equity Incentive Plan to add 5,097,095 authorized shares of common stock and to factor ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.